L01CE02 · Antineoplastic and immunomodulating agents
Onivyde pegylated liposomal (previously Onivyde)
Indications
ONIVYDE pegylated liposomal is indicated:- in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas,- in combination with 5-FU and LV for the treatment of metastatic adenocarcinoma of the pancreas, in adult patients who have progressed following gemcitabine based therapy.
Composition
- Active substance
- irinotecan anhydrous free-base
- International name (INN)
- irinotecan hydrochloride trihydrate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Onivyde pegylated liposomal (previously Onivyde)
- Active substance
- irinotecan anhydrous free-base
- ATC code
- L01CE02